NORTH CHICAGO Ill. May 9 2017 PRNewswire &8212; AbbVie NYSE ABBV a global biopharmaceutical company today announced promising results from CELEST a Phase 2 randomized doubleblind placebocontrolled study evaluating upadacitinib ABT494 an investigational...
↧